Cover Image
市場調查報告書

高眼壓症:開發中產品分析

Ocular Hypertension - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 219790
出版日期 內容資訊 英文 124 Pages
訂單完成後即時交付
價格
Back to Top
高眼壓症:開發中產品分析 Ocular Hypertension - Pipeline Review, H1 2018
出版日期: 2018年02月27日 內容資訊: 英文 124 Pages
簡介

高眼壓症是眼睛內壓力(一般稱作眼壓)超過一般正常範圍(大約定義在21mm Hg以上)時所引起。症狀有眼睛疼痛或充血,虹視症,及頭痛等。原因包含了人種,家族病史,近視及糖尿病。治療有手術及使用特定的藥物。

本報告提供全球治療高眼壓症所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

高眼壓症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

高眼壓症:企業開發中的的治療藥

高眼壓症:大學/機關研究中的治療藥

高眼壓症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

高眼壓症:企業開發中的產品

高眼壓症:大學/機關研究中的產品

高眼壓症的治療藥開發作的企業

  • Aerie Pharmaceuticals, Inc.
  • Allergan Plc
  • Amakem NV
  • Bausch & Lomb Incorporated
  • Can-Fite BioPharma Ltd.
  • D. Western Therapeutics Institute, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Inotek Pharmaceuticals Corporation
  • Ironwood Pharmaceuticals, Inc.
  • 興和
  • Laboratoires Thea S.A.
  • Laboratorios Sophia S.A. de C.V.
  • Lee's Pharmaceutical Holdings Limited
  • Lexicon Pharmaceuticals, Inc.
  • NicOx S.A.
  • Ocular Therapeutix, Inc.
  • 大塚集團
  • pSivida Corp.
  • Sanofi
  • 參天製藥
  • 千壽製藥
  • Sylentis S.A.U.
  • ViSci Ltd.

高眼壓症:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

高眼壓症:暫停中的計劃

高眼壓症:開發中止的產品

高眼壓症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10199IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ocular Hypertension - Pipeline Review, H1 2018, provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape.

Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea and bleeding at the optic nerve head. Treatment includes eye drops to reduce intraocular pressure.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ocular Hypertension - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ocular Hypertension (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 11, 14, 4 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Ocular Hypertension (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ocular Hypertension (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Ocular Hypertension (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ocular Hypertension (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ocular Hypertension (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ocular Hypertension (Ophthalmology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ocular Hypertension (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ocular Hypertension (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ocular Hypertension - Overview
    • Ocular Hypertension - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Ocular Hypertension - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Ocular Hypertension - Companies Involved in Therapeutics Development
    • Aerie Pharmaceuticals Inc
    • Aerpio Therapeutics Inc
    • Allergan Plc
    • Can-Fite BioPharma Ltd
    • D. Western Therapeutics Institute Inc
    • F. Hoffmann-La Roche Ltd
    • Ironwood Pharmaceuticals Inc
    • Laboratoires Thea SA
    • Laboratorios Sophia SA de CV
    • Lee's Pharmaceutical Holdings Ltd
    • Neurim Pharmaceuticals Ltd
    • NicOx SA
    • Novartis AG
    • Ocular Therapeutix Inc
    • Santen Pharmaceutical Co Ltd
    • Senju Pharmaceutical Co Ltd
    • Shire Plc
    • Sun Pharma Advanced Research Company Ltd
    • Sylentis SAU
    • Taejoon Pharm Co Ltd
  • Ocular Hypertension - Drug Profiles
    • (bimatoprost + timolol) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (latanoprost + netarsudil mesylate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (latanoprost + timolol maleate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AKB-9778 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bamosiran - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bimatoprost ocular insert - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bimatoprost SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brimonidine tartrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Target Matrix Metalloproteinase 1 for Steroid Induced Glaucoma and Ocular Hypertension - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • H-1129 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IWP-953 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • latanoprost - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • latanoprost SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • latanoprost SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • latanoprost SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • levobetaxolol hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MGV-354 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCX-1653 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCX-470 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCX-667 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • netarsudil mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omidenepag isopropyl - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • piclidenoson - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • piromelatine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRO-067 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRO-122 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-7945 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RO-5093151 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sepetaprost - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SHP-639 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SJP-0125 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SJP-0135 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • timolol maleate CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TJO-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • travoprost ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • travoprost SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • travoprost XR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Ocular Hypertension - Dormant Projects
  • Ocular Hypertension - Discontinued Products
  • Ocular Hypertension - Product Development Milestones
    • Featured News & Press Releases
      • Dec 18, 2017: Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa (netarsudil ophthalmic solution) 0.02% for the Lowering of Elevated Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension
      • Nov 27, 2017: Santen Files for Manufacturing and Marketing Approval of Glaucoma and Ocular Hypertension Drug Candidate DE-117 (JAN: Omidenepag Isopropyl)
      • Nov 16, 2017: Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan
      • Oct 13, 2017: Aerie Pharmaceuticals Announces FDA Advisory Committee Vote in Favor of Rhopressa (netarsudil ophthalmic solution) 0.02%
      • Sep 20, 2017: Aerie Pharmaceuticals Announces FDA Advisory Committee Meeting for Rhopressa (netarsudil ophthalmic solution) 0.02%
      • Sep 06, 2017: Aerie Pharmaceuticals Initiates Mercury 3 Clinical Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
      • Aug 08, 2017: Aerie Pharmaceuticals Comments on Notification from Contract Manufacturer
      • Jul 19, 2017: Aerie Pharmaceuticals Reports Positive Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 12-month Topline Safety Results
      • May 15, 2017: Aerie Pharmaceuticals Announces FDA Acceptance of NDA Submission for Rhopressa (netarsudil ophthalmic solution) 0.02%
      • May 09, 2017: Nicox announces the presentation of scientific data on NCX 667 at ARVO 2017
      • May 02, 2017: Ocular Therapeutix to Present Data on OTX-TP (travoprost insert) at the Association for Research in Vision and Ophthalmology Annual Meeting
      • Apr 12, 2017: Aerie Pharmaceuticals Reports Positive Rocket 4 Six-Month Topline Safety and Efficacy Results for RhopressaTM (netarsudil ophthalmic solution) 0.02%
      • Mar 15, 2017: D. Western Therapeutics Institute Announces Completion of Phase I Clinical Study with WP-1303
      • Feb 21, 2017: Nicox announces the presentation of NCX 667 scientific data at AOPT 2017
      • Jan 24, 2017: Nicox provides clinical and regulatory update for NCX 470 for IOP lowering
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Ocular Hypertension, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Ocular Hypertension - Pipeline by Aerie Pharmaceuticals Inc, H1 2018
  • Ocular Hypertension - Pipeline by Aerpio Therapeutics Inc, H1 2018
  • Ocular Hypertension - Pipeline by Allergan Plc, H1 2018
  • Ocular Hypertension - Pipeline by Can-Fite BioPharma Ltd, H1 2018
  • Ocular Hypertension - Pipeline by D. Western Therapeutics Institute Inc, H1 2018
  • Ocular Hypertension - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
  • Ocular Hypertension - Pipeline by Ironwood Pharmaceuticals Inc, H1 2018
  • Ocular Hypertension - Pipeline by Laboratoires Thea SA, H1 2018
  • Ocular Hypertension - Pipeline by Laboratorios Sophia SA de CV, H1 2018
  • Ocular Hypertension - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2018
  • Ocular Hypertension - Pipeline by Neurim Pharmaceuticals Ltd, H1 2018
  • Ocular Hypertension - Pipeline by NicOx SA, H1 2018
  • Ocular Hypertension - Pipeline by Novartis AG, H1 2018
  • Ocular Hypertension - Pipeline by Ocular Therapeutix Inc, H1 2018
  • Ocular Hypertension - Pipeline by Santen Pharmaceutical Co Ltd, H1 2018
  • Ocular Hypertension - Pipeline by Senju Pharmaceutical Co Ltd, H1 2018
  • Ocular Hypertension - Pipeline by Shire Plc, H1 2018
  • Ocular Hypertension - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2018
  • Ocular Hypertension - Pipeline by Sylentis SAU, H1 2018
  • Ocular Hypertension - Pipeline by Taejoon Pharm Co Ltd, H1 2018
  • Ocular Hypertension - Dormant Projects, H1 2018
  • Ocular Hypertension - Dormant Projects, H1 2018 (Contd..1), H1 2018
  • Ocular Hypertension - Discontinued Products, H1 2018
  • Ocular Hypertension - Discontinued Products, H1 2018 (Contd..1), H1 2018

List of Figures

  • Number of Products under Development for Ocular Hypertension, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top